Carregando empresa
Just reported
Q2 FY2027 results
From Haemonetics's results release of 5 de novembro de 2026; its quarterly report has since been filed.
Revenue
Actual
US$ 357,8M
+9,3% y/y
+5,4% q/qGuided
—
No guide given
EPS, GAAP
Actual
US$ 1,00
+23% y/y
+39% q/qGuided
—
No guide given
Operating income, GAAP
Actual
US$ 75,1M
+28% y/y
+31% q/qGuided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Haemonetics is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Medical Devices
Graded A or B and worth $2B or more: A first, then the largest.
MDTMedtronic plcUS$ 129,2BA+
SYKStryker Corp.US$ 118,9BA+
EWEdwards Lifesciences CorporationUS$ 60,9BA+
GEHCGE Healthcare Technologies Inc.US$ 37BA
GKOSGlaukos CorpUS$ 14,6BA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 de out. de 2026CBGraded C, now B
MCKMckesson Corporation4 de nov. de 2026BAGraded B, now A
CVSCVS Health Corp4 de nov. de 2026BAGraded B, now A- EWEdwards Lifesciences Corporation4 de nov. de 2026BAGraded B, now A
BIIBBiogen Inc.28 de out. de 2026BAGraded B, now A
Demonstrações financeiras completas →
Construído a partir dos próprios documentos de Haemonetics Corporation entregues à Comissão de Valores Mobiliários dos EUA (SEC). Os números são os divulgados, com o histórico por ação recalculado para a base de ações de hoje. Isto descreve um negócio — não é recomendação de investimento nem sugestão de compra ou venda.
